All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Hypomethylating agent (HMA)-based therapies are used in combination with venetoclax for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. However, it remains unclear whether the addition of venetoclax to HMA is beneficial in the treatment of older patients with TP53-mutated AML, where standard therapies do not yield an adequate response and therefore lead to a poor prognosis.
Here, we summarize results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND) study, published by Badar et al.1 in Blood Cancer Journal, comparing HMA + venetoclax with HMA-based therapy alone in the treatment of newly diagnosed TP53-mutated AML.
Figure 1. Outcomes in patients with TP53-mutated AML treated with HMA with or without venetoclax*
AML; acute myeloid leukemia; DOR, duration of response; EFS, event-free survival; HMA, hypomethylating agent; OS, overall survival.
*Data from Badar, et al.1
Key learnings |
---|
|
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox